Immunotherapeutics for breast cancer

Current Opinion in Oncology

Volumn 25, Issue 6, 2013, Pages 602-608

  Criscitiello, Carmen ^a   Curigliano, Giuseppe ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

breast cancer; immunotherapy; tumor infiltrating lymphocytes

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTIGEN; ANTIMETABOLITE; CANCER VACCINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; GLUCOCORTICOID; METHOTREXATE; MONOCLONAL ANTIBODY; OXALIPLATIN; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ADAPTIVE IMMUNITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; COLORECTAL CANCER; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CANCER VACCINES; CTLA-4 ANTIGEN; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES, CYTOTOXIC; TUMOR ESCAPE;

EID: 84885420987     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000020     Document Type: Review

References (65)

1. Disis ML. Immune regulation of cancer. J Clin Oncol 2010; 28:4531-4538.
2. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-1570.
3. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Ann Rev Immunol 2004; 22:329-360.
4. Tan PH, Lota AS. Interaction of current cancer treatments and the immune system: implications for breast cancer therapeutics. Expert Opin Pharmac-other 2008; 9:2639-2660.
5. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8:59-73.
6. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011; 8:151-160.
7. Zitvogel L, Apetoh L, Ghiringhelli F, et al. The anticancer immune response: indispensable for therapeutic success? J Clin Investig 2008; 118:1991-2001.
8. Lake RA, Robinson BW. Immunotherapy and chemotherapy: a practical partnership. Nat Rev Cancer 2005; 5:397-405.
9. van der Most RG, Currie AJ, Robinson BW, Lake RA. Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all. Cell Death Differ 2008; 15:13-20.
10. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13:1050-1059.
11. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13:54-61.
12. Apetoh L, Ghiringhelli F, Tesniere A, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007; 220:47-59.
13. Casares N, Pequignot MO, Tesniere A, et al. Caspase-dependent immuno-genicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202:1691-1701.
14. Mattarollo SR, Loi S, Duret H, et al. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res 2011; 71:4809-4820.
15. Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity. Cell; 140:798-804.
16. Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nature Rev Immunol 2009; 9:353-363.
17. Sheard CR, Reilly F, Tee DE, et al. The effect of adjuvant cyclophosphamide or tamoxifen on the numbers of lymphocytes bearing T cell or NK cell markers. Br J Cancer 1986; 54:705-709.
18. Periti P, Mini E. Immunomodulation by cancer chemotherapeutic agents. Chemioterapia 1987; 6:399-402.
19. Rozkova D, Horvath R, Bartunkova J, Spisek R. Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of Toll-like receptors. Clin Immunol 2006; 120:260-271.
20. Chiossone L, Vitale C, Cottalasso F, et al. Molecular analysis of the methyl-prednisolone-mediated inhibition of NK-cell function: evidence for different susceptibility of IL-2-versus IL-15-activated NK cells. Blood 2007; 109:3767-3775.
21. Schuerwegh AJ, van Offel JF, Bridts CH, et al. Influence of long-term therapy with methotrexate and low dose corticosteroids on type 1 and type 2 cytokine production in CD4+ and CD8+ T lymphocytes of patients with rheumatoid arthritis. J Rheumatol 2001; 28:1793-1799.
22. Schiavoni G, Mattei F, Di Pucchio T, et al. Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 2000; 95:2024-2030.
23. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56:641-648.
24. Chakraborty M, Abrams SI, Coleman CN, et al. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 2004; 64:4328-4337.
25. Carson WE 3rd, Shapiro CL, Crespin TR, et al. Cellular immunity in breast cancer patients completing taxane treatment. Clin Cancer Res 2004; 10:3401-3409.
26. Demaria S, Volm MD, Shapiro RL, et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 2001; 7:3025-3030.
27. Machiels JP, Reilly RT, Emens LA, et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macro-phage- colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 2001; 61:3689-3697.
28. Yu B, Kusmartsev S, Cheng F, et al. Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer. Clin Cancer Res 2003; 9:285-294.
29. Suzuki E, Kapoor V, Jassar AS, et al. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11:6713-6721.
30. Nowak AK, Robinson BW, Lake RA. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immu-notherapy. Cancer Res 2002; 62:2353-2358.
31. Galetto A, Buttiglieri S, Forno S, et al. Drug-and cell-mediated antitumor cytotoxicities modulate cross-presentation of tumor antigens by myeloid dendritic cells. Anticancer Drugs 2003; 14:833-843.
32. Correale P, Aquino A, Giuliani A, et al. Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro. Int J Cancer 2003; 104:437-445.
33. Ghiringhelli F, Apetoh L, Tesniere A, et al. Activation of the NLRP3 inflamma-some in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15:1170-1178.
34. Sluyter R, Dalitz JG, Wiley JS. P2X7 receptor polymorphism impairs extracellular adenosine 5'-triphosphate-induced interleukin-18 release from human monocytes. Genes Immun 2004; 5:588-591.
35. Brufsky A. Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care. Am J Clin Oncol; 33:186-195.
36. Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009; 14:320-368.
37. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26:1789-1796.
38. Tamura K, Shimizu C, Hojo T, et al. Fc{gamma}R2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann Oncol 2011; 22:1302-1307.
39. Stagg J, Loi S, Divisekera U, et al. Anti-ErbB-2 mAb therapy requires type Iand II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci USA 2011; 108:7142-7147.
40. Park S, Jiang Z, Mortenson ED, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010; 18:160-170.
41. Rakhra K, Bachireddy P, Zabuawala T, et al. CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 2010; 18:485-498.
42. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent antiprogrammed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28:3167-3175.
43. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
44. Persson J, Beyer I, Yumul R, et al. Immuno-therapy with anti-CTLA4 antibodies in tolerized and non-tolerized mouse tumor models. PloS One 2011; 6:e22303.
45. Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancertrial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013; 31:860-867.
46. Parmiani G, De Filippo A, Novellino L, Castelli C. Unique human tumor antigens: immunobiology and use in clinical trials. J Immunol 2007; 178:1975-1979.
47. Parmiani G, Russo V, Marrari A, et al. Universal and stemness-related tumor antigens: potential use in cancer immunotherapy. Clin Cancer Res 2007; 13:5675-5679.
48. Curigliano G, Locatelli M, Fumagalli L, Goldhirsch A. Immunizing against breast cancer: a new swing for an old sword. Breast 2009; 18 (Suppl 3):S51-S54.
49. Chung MA, Luo Y, O'Donnell M, et al. Development and preclinical evaluation of a Bacillus Calmette-Guerin-MUC1-based novel breast cancer vaccine. Cancer Res 2003; 63:1280-1287.
50. Disis ML, Schiffman K, Guthrie K, et al. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein-based vaccine. J Clin Oncol 2004; 22:1916-1925.
51. Hodge JW. Carcinoembryonic antigen as a target for cancer vaccines. Cancer Immunol Immunother 1996; 43:127-134.
52. Bednarek AK, Sahin A, Brenner AJ, et al. Analysis of telomerase activity levels in breast cancer: positive detection at the in situ breast carcinoma stage. Clin Cancer Res 1997; 3:11-16.
53. Stauss HJ, Thomas S, Cesco-Gaspere M, et al. WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells. Blood Cells Mol Dis 2008; 40:113-116.
54. Rivoltini L, Canese P, Huber V, et al. Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control? Expert Opin Biol Ther 2005; 5:463-476.
55. Goydos JS, Elder E, Whiteside TL, et al. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 1996; 63:298-304.
56. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Investig 2001; 107:477-484.
57. MacLean GD, Miles DW, Rubens RD, et al. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother Emphasis Tumor Immunol 1996; 19:309-316.
58. Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anticarcinoembryonic antigen immune responses. J Clin Oncol 2000; 18:3964-3973.
59. Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 2005; 65:8059-8064.
60. Emens LA. Chemotherapy and tumor immunity: an unexpected collaboration. Front Biosci 2008; 13:249-257.
61. Finn OJ. Cancer immunology. N Engl J Med 2008; 358:2704-2715.
62. Hoos A, Parmiani G, Hege K, et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother 2007; 30: 1-15.
63. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-422.
64. Tyagi P, Mirakhur B. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 2009; 10:371-374.
65. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med; 364:2119-2127.